drugset / Trial / NCT01388621
Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this trial is to estimate the therapeutic efficacy of the experimental targeted regimen including the EGFR antibody panitumumab (in combination with carboplatin and either pegylated liposomal doxorubicin or gemcitabine) in relation to the respective standard combination in patients with a KRAS wildtype with platinum-sensitive recurrent ovarian cancer. It is expected that the progression free survival rate at 12 months is improved by the targeted regimen.
Timeline
- Start
- 2011-10
- Primary completion
- 2014-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab | Monoclonal antibody | 6 mg/kg | — |
| Subject | Panitumumab | Monoclonal antibody | 9 mg/kg | — |
| Background | Carboplatin | Small molecule | 4 unknown | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | pegylated liposomal doxorubicin (PLD) | Unknown | 30 mg/m2 | — |